According to a study, Statin drug may put aside the risk of heart attack in patients.

Pfizer Inc.’s Lipitor stated that the world’s best selling prescription drug, within 24 hours of admission for a heart attack could markedly diminish the risk of early complications and of fading in the hospital.

Dr. Gregg C. Fonarow, from the University of California Los Angeles said this is the largest study to look at whether very near the beginning use of Statin therapy after a heart attack can influence clinical outcomes”.

The research led by Fonarow involved comparing records of more than 170,000 patients in the National Registry of Myocardial Infarction.
The registry has collected data on more than 2.3 million heart-attack patients since 1990.

Fonarow said, “The benefits of the therapy carry on for several years beyond discharge.

Wright, a cardiologist who took part in the study said, “It shows enhanced long-term survival and as the current report deals only with survival in the hospital, analysis of the data from the study, is published in a different journal.